Clinical Scorecard: Creation and assessment of a transparent predictive model utilizing spatial distribution of tumor-infiltrating lymphocytes in H&E whole-slide images for immune classification of lung adenocarcinoma

At a Glance

Key Highlights

• Developed a predictive model for immune subtyping based on TIL spatial distribution.
• High-immunity subgroup showed increased CD8+ T cells and M1 macrophages.
• Model achieved AUC of 0.927 in external validation for immune subtype classification.
• Automated annotation model demonstrated high accuracy in tissue segmentation and TIL identification.
• Cost-effective tool for assessing tumor immune status.

Guideline-Based Recommendations

Diagnosis

• Utilize spatial distribution of TILs in H&E images for immune classification.

Management

• Integrate immune subtype classification into treatment planning for immunotherapy.

Monitoring & Follow-up

• Regular assessment of TIL spatial distribution to evaluate treatment response.

Risks

• Low-immunity status may indicate poor response to immunotherapy.

Patient & Prescribing Data

Patients diagnosed with lung adenocarcinoma, particularly those considering immunotherapy.

Identification of high-immunity patients may guide the use of immune checkpoint inhibitors.

Clinical Best Practices

• Employ automated image analysis for objective assessment of TILs.
• Combine transcriptomic data with spatial analysis for comprehensive immune profiling.
• Ensure transparency and verifiability in predictive modeling processes.

References

• Study on immune microenvironment and immunotherapy response
• Role of TILs in lung adenocarcinoma prognosis
• Digital pathology and AI in oncology